NZ606589A - 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof - Google Patents

5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof

Info

Publication number
NZ606589A
NZ606589A NZ606589A NZ60658911A NZ606589A NZ 606589 A NZ606589 A NZ 606589A NZ 606589 A NZ606589 A NZ 606589A NZ 60658911 A NZ60658911 A NZ 60658911A NZ 606589 A NZ606589 A NZ 606589A
Authority
NZ
New Zealand
Prior art keywords
dihydroquinoline
carboxamide
oxo
chloro
hydroxy
Prior art date
Application number
NZ606589A
Other languages
English (en)
Inventor
Ulf Tomas Fristedt
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of NZ606589A publication Critical patent/NZ606589A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
NZ606589A 2010-07-09 2011-07-08 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof NZ606589A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39926410P 2010-07-09 2010-07-09
PCT/US2011/043391 WO2012006544A1 (en) 2010-07-09 2011-07-08 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof

Publications (1)

Publication Number Publication Date
NZ606589A true NZ606589A (en) 2015-03-27

Family

ID=45439027

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ606589A NZ606589A (en) 2010-07-09 2011-07-08 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof

Country Status (14)

Country Link
US (3) US20120010239A1 (cg-RX-API-DMAC10.html)
EP (2) EP3056205A1 (cg-RX-API-DMAC10.html)
JP (2) JP5934202B2 (cg-RX-API-DMAC10.html)
KR (1) KR20130041193A (cg-RX-API-DMAC10.html)
CN (1) CN102985090B (cg-RX-API-DMAC10.html)
AU (2) AU2011274502A1 (cg-RX-API-DMAC10.html)
BR (1) BR112013000607A2 (cg-RX-API-DMAC10.html)
CA (1) CA2804989A1 (cg-RX-API-DMAC10.html)
EA (1) EA201390074A1 (cg-RX-API-DMAC10.html)
HK (1) HK1225308A1 (cg-RX-API-DMAC10.html)
MX (1) MX2013000332A (cg-RX-API-DMAC10.html)
NZ (1) NZ606589A (cg-RX-API-DMAC10.html)
WO (1) WO2012006544A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201300957B (cg-RX-API-DMAC10.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0617477A2 (pt) * 2005-10-19 2011-07-26 Teva Pharma mistura de partÍculas cristalinas de laquinimod sàdica, composiÇço, processo de cristalizaÇço de laquinimod sàdica, laquinimod sàdica, e, processo para produzir uma composiÇço farmacÊutica
CN101466379B (zh) 2006-06-12 2012-10-31 泰华制药工业有限公司 稳定的拉喹莫德的制剂
WO2009082471A1 (en) 2007-12-20 2009-07-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
NZ597378A (en) * 2009-06-19 2014-08-29 Teva Pharma Treatment of multiple sclerosis with laquinimod
BR112012002124A2 (pt) * 2009-07-30 2015-09-15 Teva Pharma tratamento da doença de crohn com laquinimode.
WO2011019375A1 (en) 2009-08-10 2011-02-17 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
KR20130006640A (ko) 2010-03-03 2013-01-17 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 루푸스 신장염의 치료
EA201290860A1 (ru) * 2010-03-03 2013-04-30 Тева Фармасьютикал Индастриз Лтд. Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата
AU2011274496B2 (en) 2010-07-09 2016-03-10 Teva Pharmaceutical Industries Ltd. Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
SG11201401330YA (en) 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod
WO2013116657A1 (en) 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
MX2014009889A (es) 2012-02-16 2014-11-13 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
CN103626701A (zh) * 2012-08-28 2014-03-12 天津药物研究院 一种制备喹啉衍生物的方法
CN103626702A (zh) * 2012-08-30 2014-03-12 天津药物研究院 一种制备喹啉酮衍生物的方法
EA201590788A1 (ru) 2012-11-07 2015-12-30 Тева Фармасьютикал Индастриз Лтд. Аминные соли лахинимода
JP2016514162A (ja) * 2013-03-14 2016-05-19 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドナトリウムの結晶およびその製造のための改善された方法
WO2014152009A1 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Transdermal formulations of laquinimod
HK1231413A1 (zh) 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德
US20190090046A1 (en) * 2017-09-21 2019-03-21 Bragi GmbH Tactile Feedback for Audio Defined Menu System and Method
GB202006390D0 (en) * 2020-04-30 2020-06-17 Aqilion Ab Novel treatments

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2380420A (en) * 1940-12-16 1945-07-31 William S Emerson Production of secondary and tertiary amines from nitrogen compounds
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
DE3724018A1 (de) * 1987-07-21 1989-02-02 Bayer Ag Verfahren zur trennung von anilin-derivaten
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
US6875869B2 (en) 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
SE0201778D0 (sv) * 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) * 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
BRPI0617477A2 (pt) 2005-10-19 2011-07-26 Teva Pharma mistura de partÍculas cristalinas de laquinimod sàdica, composiÇço, processo de cristalizaÇço de laquinimod sàdica, laquinimod sàdica, e, processo para produzir uma composiÇço farmacÊutica
CN101466379B (zh) 2006-06-12 2012-10-31 泰华制药工业有限公司 稳定的拉喹莫德的制剂
WO2009082471A1 (en) * 2007-12-20 2009-07-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
US8354428B2 (en) * 2008-07-01 2013-01-15 Actavis Group Ptc Ehf Solid state forms of laquinimod and its sodium salt
WO2010070449A2 (en) * 2008-12-17 2010-06-24 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof

Also Published As

Publication number Publication date
AU2017261621A1 (en) 2017-12-07
ZA201300957B (en) 2014-04-30
HK1225308A1 (en) 2017-09-08
CA2804989A1 (en) 2012-01-12
EA201390074A1 (ru) 2013-06-28
US20180140592A1 (en) 2018-05-24
EP2590653A1 (en) 2013-05-15
CN102985090B (zh) 2014-11-26
EP2590653A4 (en) 2014-01-01
JP5934202B2 (ja) 2016-06-15
AU2011274502A1 (en) 2013-02-28
EP3056205A1 (en) 2016-08-17
MX2013000332A (es) 2013-02-26
CN102985090A (zh) 2013-03-20
JP2013534536A (ja) 2013-09-05
US20160279121A1 (en) 2016-09-29
JP2016053049A (ja) 2016-04-14
WO2012006544A1 (en) 2012-01-12
BR112013000607A2 (pt) 2016-06-28
KR20130041193A (ko) 2013-04-24
US20120010239A1 (en) 2012-01-12

Similar Documents

Publication Publication Date Title
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
MY162655A (en) Metal salt compositions
MX338327B (es) Inhibidores de cdk.
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
GB201106743D0 (en) Novel compounds
IN2015DN01156A (cg-RX-API-DMAC10.html)
MY158992A (en) Forms of rifaximin and uses thereof
UY34350A (es) Derivados de pirazolquinolinona, su preparación y su uso terapéutico.
MY179933A (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use thereof
PH12013500500A1 (en) Fused heteroaryls and their uses
MX2016008448A (es) Conjugados de var2csa-farmaco.
UA116395C2 (uk) ПОХІДНІ ТРИАЗОЛ[4,5-b]ПІРИМІДИНУ
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX2020002544A (es) Sales de glicopirrolato.
PH12015501088A1 (en) Dimeric compounds
MY161601A (en) Films and compositions comprising the same
MX2012010127A (es) Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos.
MX381841B (es) Anticuerpos anti-jagged y métodos de uso.
PH12015500399A1 (en) Azaindolines
IN2015DN00085A (cg-RX-API-DMAC10.html)
AU2013338098A8 (en) Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof
MX2013005624A (es) Nuevos derivados de indolizina, su preparacion y su aplicacion en terapeutica.
UA70698U (ru) Применение 2-метил-3-фениламинометилхинолин-4-она как противогипоксического, актопротекторного и антиалкогольного средства
UA59797U (ru) Применение амкесола как вещества с противокашлевыми свойствами
UA80533U (uk) (s)-(+)-n,n-диметил-3-(1-нафтален-1-ілокси)-1-фенілпропан-1-амін та його фармацевтично прийнятні солі

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2016 BY DENNEMEYER + CO.

Effective date: 20150911

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2017 BY DENNEMEYER + CO

Effective date: 20160622

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2018 BY DENNEMEYER + CO

Effective date: 20170623

LAPS Patent lapsed